In this study out of 69 ESCC patients, strong COX-2 expression was observed in 67% of the tumor tissue of ESCC patients whereas negative COX-2 expression was observed in 33% of patients including both the 80% true negative and 20% weakly positive (Fig 2). The gene discussed is PTGS2; the disease is neoplasm.